Abstract
The course of endocrine ophthalmopathy was investigated on the basis of clinical and biochemical parameters and in relation to different therapeutic strategies. A retrospective appraisal was made of 297 patients (44 ± 14 yr, 249 women) with inclusion of anamnestic and clinical data as well as the results of computer tomography. At the beginning of therapy, 253 patients were hyperthyroid, 36 were euthyroid and eight were hypothyroid. The HLA typing carried out in 89 patients showed the phenotypes B8 and DR3 in 32% and 42% of the cases, respectively. Raised microsomal antibodies were present in 56% of the patients and there were raised thyroglobulin antibodies in 19%. Sixty-three % of the patients received immu-nosuppressants in the course of therapy: glucocorticoids in all cases, nonsteroid immunosuppressants in 15%. Eight % of the patients were irradiated retrobulbarly. The inflammatory parameters could be favorably affected, whereas eye muscle involvement and bulbar protrusion proved to be more resistant to therapy. In patients with combined immunosuppressant therapy or steroids + retrobulbar radiation, there were unequivocal successes with regard to the proptosis, vision and intraocular pressure. None of the strategies applied constitutes an optimal treatment with regard to the long-term course. Following therapy, there is an improvement of endocrine ophthalmopathy, but not complete healing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jacobson D.H., Gorman C.A. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr. Rev. 5:200, 1984.
Kahaly G., Beyer J. Immunosuppressant therapy of thyroid eye disease. Klin. Wochenschr. 66:1049, 1988.
Horster F.A., Wildmeister W. Endokrine Orbitopathie: Therapieerfolg bei 148 Patienten unter Berücksichtigung neuer pathogenetischer Aspekte. Dtsch. Med. Wschr. 108: 413, 1983.
Schifferdecker E., Schulz F., Rosak C., Althoff P.H. Verlauf der endokrinen Ophthalmopathie und Effektivität der etablierten therapeutischen Maßnahmen. Med. Klin. 87:779, 1986.
Werner S.C. Modification of the classification of the eye changes of Graves’ disease. J. Clin. Endocrinol. Metab. 44: 203, 1977.
Albert E.D., Baur M.P., Mayr W. Histocompatibility testing. Springer-Verlag, Berlin-Heidelberg-New York-Tokyo, 1984.
Kahaly G., Schrezenmeir J., Krause U., Schweikert B., Meuer S., Müller W., Dennebaum R., Beyer J. Ciclosporin and prednisone versus prednisone in treatment of Graves’ ophthalmopathy: A controlled, randomized and prospective study. Eur. J. Clin. Invest. 76:415, 1986.
Utech C., Wulle K.G., Biegler E.U., Pfannenstiel P., Panitz N., Kiefer H. Treatment of severe Graves’ ophthalmopathy with Ciclosporin A. Acta Endocrinol. (Copenh.) 110: 493, 1985.
Weetman A.P., McGregor A.M., Ludgate M., Beck L., Mills P.V., Lazarus J.H., Hall R. Cyclosporin improves Graves’ ophthalmopathy. Lancet 2: 486, 1983.
Borel J.F., Ryffel B. The mechanism of action of Ciclosporin: A continuing puzzle. In: Schindler R. (Ed.), Cyclosporin in autoimmune diseases. Springer-Verlag Berlin-Heidelberg-New York-Tokyo, 1985.
Bicker U., Usadel K.H. Ciamexone, a highly selective immunomodulator — a tool for autoimmune disease? Klin. Wochenschr. 64:1261, 1986.
Bartalena L., Marcocci C., Chiovato L., Laddaga M., Lepri G., Andreani D., Cavallacci G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J. Clin. Endocrinol. Metab. 56:1139, 1983.
Marcocci C., Bartalena L., Panicucci M., Marconcini C., Cartei F., Cavallacci G., Laddaga M., Campobasso G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin. Endocrinol. (Oxf.) 27: 33, 1987.
Aranow H., Day R.M.: Management of thyrotoxicosis in patients with ophthalmopathy: antithyroid regimen determined primarily by ocular manifestations. J. Endocrinol. 25:1, 1965.
Solem J.H., Seegard E., Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med. Scand. 205:111, 1979.
Hales J.B., Rundle F.F. Ocular changes in Graves’ disease. Quart. J. Med. 29: 113, 1960.
Gorman C.A. Temporal relationship between onset of Graves’ ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin. Proc. 58: 515, 1983.
Marcocci C., Bartalena L., Bogazzi F., Panicucci M., Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol. (Copenh.) 120: 473, 1989.
Mornex R., Fournier G., Berthezene F. Ophthalmic Graves’ disease. Mod. Prob. Ophthalmol. 14: 426, 1975.
Wiersinga W.M., Smit T., van der Gaag R., Koorneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kahaly, G., Böckmann, H., Beyer, J. et al. Long-term observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures. J Endocrinol Invest 13, 287–292 (1990). https://doi.org/10.1007/BF03349564
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349564